拜耳集团Bayer（BAYZF）2023年第一季度财报「OTC」（英文版）（17页）.pdf

1、 Slow start to the year as expected/Group sales stable at 14.4 billion (Fx&p adj.1.1%)/Accelerated normalization in glyphosate business good price dynamics in other Crop Science units/New Pharmaceuticals products deliver strong growth;headwinds in China/Consumer Health continues to grow/EBITDA befor

2、e special items:4.5 billion(14.9%)/Glyphosate and inflation weigh on earnings/Pharmaceuticals maintains high R&D investment/Core earnings per share at 2.95 (16.4%)/Net income at 2.2 billion/Free cash flow at minus 4.1 billion/Group outlook confirmed;target attainment at lower end of guidanceQuarterl

3、y Statement First Quarter of 2023 Bayer Quarterly Statement as of March 31,2023 2Bayer Group Key Data Change(%)million Q1 2022Q1 2023ReportedFx&p adj.Sales 14,639 14,389 1.7 1.1Change in sales1 Volume+5.6%5.8%Price+8.7%+4.7%Currency+4.2%+0.7%Portfolio+0.2%1.3%Sales by region Europe/Middle East/Afric

4、a 4,514 4,639+2.8+5.4North America 5,962 5,906 0.9 3.1Asia/Pacific 2,411 2,181 9.5 4.3Latin America 1,752 1,663 5.1 7.0EBITDA1 5,292 4,318 18.4Special items1 41(153)EBITDA before special items1 5,251 4,471 14.9EBITDA margin before special items1 35.9%31.1%EBIT1 4,212 2,973 29.4Special items1 40(431)

5、EBIT before special items1 4,172 3,404 18.4Financial result(490)(367)25.1Net income(from continuing and discontinued operations)3,291 2,178 33.8Earnings per share from continuing and discontinued operations()3.35 2.22 33.7Core earnings per share1 from continuing operations()3.53 2.95 16.4Net cash pr

6、ovided by(used in)operating activities (from continuing and discontinued operations)(726)(3,550).Free cash flow1(1,187)(4,102).Net financial debt(at end of period)34,527 36,077+4.5Cash flow-relevant capital expenditures (from continuing and discontinued operations)349 466+33.5Research and developmen